Systematic evaluation for efficacy of tripterygium glycosides in treating diabetic nephropathy stage IV.
- Author:
Jing HUANG
;
Ji-qiang ZHANG
;
Zheng CHEN
;
Yan ZHANG
;
Wei-dong CHEN
;
Xue-ping WU
- Publication Type:Journal Article
- MeSH:
Angiotensin Receptor Antagonists;
administration & dosage;
Angiotensin-Converting Enzyme Inhibitors;
administration & dosage;
Diabetic Nephropathies;
drug therapy;
Drug Therapy, Combination;
Glycosides;
administration & dosage;
Humans;
Tripterygium;
chemistry
- From:
China Journal of Chinese Materia Medica
2015;40(15):3100-3109
- CountryChina
- Language:Chinese
-
Abstract:
To systematically evaluate the efficacy and safety of tripterygium glycosides (TG) combined with ACEI/ARB preparation in treating diabetic nephropathy stage IV. The computer retrievals were made in Cochrane Libarary, PubMed, Embase, SCI, Sinnomed, CNKI, Chinainfo and VIP, and hand retrievals were conducted for meeting and academic papers (updated to December 30, 2014), in order to collect randomized controlled trials and quasi-randomized control trials for TG combined with ACEI/ARB preparation in treating diabetic nephropathy stage IV and set the literature inclusion and elimination standards. Eligible literatures were included and evaluated according to standards in Cochrane Handbook. RevMan 5.3 and Stata 12.0 were used for a Meta-analysis. A total of 13 randomized controlled trials and quasi-randomized control trials involving 1119 patients with diabetic nephropathy were included. The Meta analysis result showed that compared with the control group, the combination group showed better effects in reducing the 24-hour urinary protein [MD = -0.84, 95% CI (-1.02, -0.66)], raising albumin [SMD = 0.98, 95% CI (0.81, 1.16)], the total efficiency [OR = 4.23, 95% CI (2.77, 6.46)] and the significant efficiency [OR = 5.35, 95% CI (2.70, 10.60)], with no statistical difference in Serum Creatinine between Both groups [MD = -0.82, 95% CI (-4.30, 2.66), P = 0.64]. However, the risk of adverse reactions increased by 7% [RD = 0.07, 95% CI (0.03, 0.12)]. The Egger's test showed no publication bias. Tripterygium Glycosides combined with ACEI/ARB in treating diabetic nephropathy stage IV is supper than the single administration of ACEI/ARB, with a good prospect in clinical application. Nevertheless, due to the small-size and low-quality samples in this study, more high-quality and large sample-size randomized controlled trials shall be conducted to verify the findings.
